According to a new report, published by KBV research, The Global Congestive Heart Failure (CHF) Treatment Devices Market size is expected to reach $16.5 billion by 2028, rising at a market growth of 5.4% CAGR during the forecast period.
The Implantable Cardioverter Defibrillators market is expected to witness a CAGR of 5.6% during (2022 - 2028). The increasing growth of this segment is attributed to its capacity to perform three main functions viz. Defibrillation, Cardioversion, and Cardiac pacing. Moreover, this is due to the fact that defibrillators and pacemakers are used as the first line of treatment for cardiac failure, Due to which, the demand for defibrillators. Hence, this factor is fueling the growth of this segment.
The North America market dominated the Global Congestive Heart Failure (CHF) Treatment Devices Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $5.9 Billion by 2028. The Europe market is estimated to witness a CAGR of 5.2% during (2022 - 2028). Additionally, The Asia Pacific market would experience a CAGR of 5.9% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/congestive-heart-failure-treatment-devices-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Boston Scientific Corporation, MicroPort Scientific Corporation, Abbott Laboratories, Medtronic PLC, Abiomed, Inc., Berlin Heart GmbH, Jarvik Heart, Inc., Lepu Medical Technology (Beijing) Co., Ltd., BIOTRONIK SE & Co. KG, and Osypka Medical GmbH.
By Product Type
By Geography
Companies Profiled
Unique Offerings 
